- 2008 Annual Report (PDF 469 Kb)
- 2009 - First quarter (PDF 277 Kb)
Current Strategy
Ambrilia is a biotechnology company listed on the Toronto Stock Exchange (TSX: AMB) with its offices and research and manufacturing facilities located in Montréal Québec, Canada.
The Company's current strategy is to capitalize on its broad product portfolio through out-licensing and divestment.
History
Ambrilia Biopharma was created in 2006 pursuant to the merger, via acquisition, of Procyon Biopharma, a publicly-traded Montreal-based biotechnology company that was developing innovative therapeutics in the fields of oncology and HIV/AIDS, with Cellpep S.A., a French private biotechnology with expertise in oncology and infectious diseases.

